<DOC>
	<DOCNO>NCT00179673</DOCNO>
	<brief_summary>Participants qualify receive lenalidomide daily day 1-21 every 28 day cycle . Treatment continue 52 week disease progression ; participant achieve complete response ( CR ) receive additional 2 cycle treatment prior discontinuation . Participants follow progression free survival follow discontinuation treatment phase</brief_summary>
	<brief_title>Lenalidomide ( Revlimid® , CC-5013 ) Subjects With Relapsed Refractory Indolent Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>Participants qualify enrollment study enter treatment phase receive single-agent lenalidomide 25 mg daily Days 1 21 every 28-day cycle . The treatment phase begin Day 1 Cycle 1 . Study visit schedule occur every 28 day coincide begin new cycle . The start date new cycle delay adverse event ( AEs ) occur , case visit date start follow cycle schedule 28 day actual start date delay cycle . Efficacy safety assessment , include complete blood count ( CBCs ) perform least every 2 week Cycles 1 4 treatment phase . Participants continue treatment phase study 52 week disease progression develop , lenalidomide treatment discontinue reason , study terminate .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>1 . Understand voluntarily sign informed consent form . 2 . Age great equal 18 year time signing informed consent form 3 . Able adhere study visit schedule protocol requirement 4 . Biopsyproven nonHodgkin 's lymphoma ( NHL ) 5 . Indolent lymphoma follow histology acceptable : 1 . Follicular center lymphoma , grade 1 , 2 , 2 . Extranodal marginal zone Bcell lymphoma mucosaassociated lymphoid tissue ( MALT ) type , 3 . Nodal marginal zone Bcell lymphoma 4 . Splenic marginal zone Bcell lymphoma , 5 . Small lymphocytic lymphoma , 6 . Lymphoplasmacytoid lymphoma 6 . Relapsed refractory previous therapy lymphoma . Participants must receive least one prior treatment regimen radiation , immunotherapy , chemotherapy , OR radioimmunotherapy , ineligible unwilling undergo autologous stem cell transplant . There limit number prior therapy 7 . Participants must measurable disease cross sectional imaging least 2 cm long diameter 8 . Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 , 1 2 9 . Females childbearing potential ( FCBP ) must agree use two reliable form contraception practice complete abstinence heterosexual intercourse follow period 1 ) least 28 day start study drug ; 2 ) participate study ; 3 ) least 28 day discontinuation study . The two method reliable contraception must include one highly effective method ( i.e . intrauterine device ( IUD ) , hormonal [ birth control pill , injection , implant ] , tubal ligation , partner 's vasectomy ) one additional effective ( barrier ) method ( i.e . latex condom , diaphragm , cervical cap ) . FCBP must refer qualified provider contraceptive method need . 1 . Any following laboratory abnormality 1 . Absolute neutrophil count ( ANC ) &lt; 1,500 cells/mm^3 ( 1.5 x 10^9/L ) 2 . Platelet count &lt; 100,000/mm^3 ( 100 x 10^9/L ) 3 . Serum creatinine &gt; 2.5 mg/dL ( 221 mmol/L ) 4 . Serum glutamicoxaloacetic transaminase/ aspartate aminotransferase ( SGOT/AST ) serum glutamic : pyruvic transaminase/alanine aminotransferase ( SGPT/ALT ) &gt; 5.0 x upper limit normal ( ULN ) 5 . Serum total bilirubin &gt; 2.0 mg/dL ( 34 mmol/L ) 2 . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study . 3 . All participant Central Nervous System ( CNS ) disease exception subject whose CNS disease treat chemotherapy , radiotherapy surgery remain asymptomatic , active CNS disease , show lumbar puncture , Computed Tomography Magnetic resonance imaging ( CT scan MRI ) , least 6 month . 4 . Prior history malignancy NHL ( except basal cell squamous cell carcinoma skin carcinoma situ cervix breast ) unless subject free disease &gt; equal 1 year . 5 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form . 6 . Known positive Human Immunodeficiency Virus ( HIV ) . 7 . Pregnant lactating female . 8 . Prior ≥ grade 3 ( National Cancer InstituteCommon Terminology Criteria Adverse Events [ NCI CTCAE ] ) allergic reaction/hypersensitivity thalidomide . 9 . Prior ≥ grade 3 rash desquamating ( blister ) rash take thalidomide . 10 . Prior use lenalidomide . 11 . Use standard experimental anticancer drug therapy within 28 day day 1 study drug therapy . 12 . Known active Hepatitis C .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>NHL</keyword>
	<keyword>CC5013</keyword>
	<keyword>Non-Hodgkins Lymphoma</keyword>
	<keyword>revlimid</keyword>
	<keyword>cc-5013</keyword>
	<keyword>celgene</keyword>
</DOC>